Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: A systematic review (Q38513491)

3 September 2017

1 reference

title

Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: A systematic review (English)

1 reference

3 September 2017

1 reference

Emilio Clementi

1 reference

3 September 2017

Paolo Pellegrino

1 reference

3 September 2017

Sonia Radice

series ordinal

1 reference

3 September 2017

language of work or name

English

0 references

publication date

31 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

page(s)

3444-3449

1 reference

Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Current status of human papillomavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Current Status of Human Papillomavirus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Human papillomavirus vaccines: current status and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Systemic lupus erythematosus and the risk of malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Vaccination and autoimmune rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Abnormalities of uterine cervix in women with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Higher incidence of abnormal Pap smears in women with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Lack of association between cervical dysplasia and IBD: a large case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Paediatric rheumatic disease: Biologic therapy and risk of infection in children with JIA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

On the relationship between human papilloma virus vaccine and autoimmune diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

On the association between human papillomavirus vaccine and primary ovarian failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Can HPV immunisation cause ADEM? Two case reports and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Human papillomavirus vaccine and systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

General health maintenance in IBD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

The spectrum of post-vaccination inflammatory CNS demyelinating syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Vaccines and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

HPV vaccination: for women of all ages?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

HPV infection and cervical disease: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.041

10.1016/J.VACCINE.2015.05.041

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference